Traditional Chinese medicine reverses cancer multidrug resistance and its mechanism

被引:0
作者
J. Wei
Z. Liu
J. He
Q. Liu
Y. Lu
S. He
B. Yuan
J. Zhang
Y. Ding
机构
[1] Jilin University,Department of Laboratory Animals, College of Animal Sciences
[2] China-Japan Union Hospital of Jilin University,The Second Clinical School of Medicine, Guangdong Provincial Hospital of Chinese Medicine
[3] Guangzhou University of Chinese Medicine,Zhuhai Hospital
来源
Clinical and Translational Oncology | 2022年 / 24卷
关键词
Cancer; Multidrug resistance; Traditional Chinese medicines; Mechanism;
D O I
暂无
中图分类号
学科分类号
摘要
Chemotherapy is one of the most commonly used clinical treatments among the currently available cancer therapies. However, the phenomenon of Multidrug resistance (MDR) has become a challenge in the treatment process, weakening the impact of chemotherapy. Extensive research on elucidating the development of cancer MDR has identified the following mechanisms that play a critical role in the development of several MDR reversal agents: abnormal expression of cell membrane transporters, adaptation of cancer cells to the microenvironment, regulation of hypoxia, repair of DNA damage and reduction of apoptosis, the enhancement of the EMT process, the existence of cancer stem cells (CSCs), and the abnormal activation of key signaling pathways. However, they failed to demonstrate significant efficacy due to severe side effects during their clinical trials. Traditional Chinese medicines (TCMs) are known to play an important anti-cancer role since they have low toxicity, high efficacy, and safety and can reverse MDR. TCMs reversal agents can be divided into Chinese medicine monomers, synthetic monomers, analogs, or derivatives. Several studies have shown that TCMs can effectively overcome cancer MDR and can be effectively used for treating cancer patients.
引用
收藏
页码:471 / 482
页数:11
相关论文
共 599 条
[1]  
Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424
[2]  
Ferlay J(2020)Mechanisms of multidrug resistance in cancer chemotherapy Int J Mol Sci. 21 3233-100
[3]  
Soerjomataram I(1999)Mechanisms of altered sequestration and efflux of chemotherapeutic drugs by multidrug-resistant cells Cell Biol Toxicol 15 91-1825
[4]  
Siegel RL(2019)The multi-factorial nature of clinical multidrug resistance in cancer Drug Resist Update. 46 100645-16
[5]  
Torre LA(2017)Reversal of P-gp-mediated multidrug resistance in colon cancer by cinobufagin Oncol Rep 37 1815-128
[6]  
Jemal A(2016)Co-encapsulation of paclitaxel and baicalein in nanoemulsions to overcome multidrug resistance via oxidative stress augmentation and P-glycoprotein inhibition Int J Pharm 513 8-7105
[7]  
Bukowski K(2019)Endoplasmic reticulum stress: major player in size-dependent inhibition of P-glycoprotein by silver nanoparticles in multidrug-resistant breast cancer cells J Nanobiotechnol 17 9-80
[8]  
Kciuk M(2019)Tumor dormancy and interplay with hypoxic tumor microenvironment Int J Mol Sci. 20 4305-247
[9]  
Kontek R(2014)Resveratrol reduces the hypoxia-induced resistance to doxorubicin in breast cancer cells J Nutr Sci Vitaminol (Tokyo) 60 122-447
[10]  
Ouar Z(2019)Mitochondrial fission causes cisplatin resistance under hypoxic conditions via ROS in ovarian cancer cells Oncogene 38 7089-279